Editorial: From the Editor-in-Chief

Y. James Kang^{1,2}

Accepted: 21 December 2020 / Published online: 2 January 2021

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021

I am pleased to announce that starting from this first issue of volume 21, 2021, the journal *Cardiovascular Toxicology* expands its production from 6 issues a year to 12 issues a year. This expansion meets the high-speed growth of this journal in the evolving field of cardiovascular toxicology. With this expansion, *Cardiovascular Toxicology* will even much better serve scientific community for more frequent and higher standard dissemination of timely discoveries in the field.

In 2001, I and the publisher (Humana Press then and SpringerNature now) launched the journal with a single goal: to establish a preeminent journal in the specialized field of cardiovascular toxicology. Looking back to last 20 years' production of this journal and its impact in the field, I proudly announce that we have reached our goal. The journal started publishing quarterly, then expanded its production bimonthly in 2018, and now responded to a high demand for publishing monthly. This journal has earned a world-wide acceptance and receives manuscripts from more than 30 countries, but unfortunately, due to the limitation of publication space, only a small portion of the scientifically sound and well-performed studies have been published in this journal. It basically focused on publishing highly originally developed and mechanistic insightful studies in addition to being specialized in the field of cardiovascular toxicology. Although the focus is quite narrow, the impact of this journal is much more beyond just on academic research, extending to pharmaceutical industry, public awareness, and regulatory policies, just naming a few. These conceptual and practical impacts earned this journal a well-respected reputation in the field.

Thanks to all members of the dynamic board, dedicated associate editors, and charter members as a whole, as well as enthusiastically involved reviewers, for invaluable commitment

and contribution to the outstanding development of this journal. Every single manuscript has been gone through an initial evaluation for suitability of the topic to the scope of this journal and for rigidity of scientific performance. Manuscripts passing the initial screening process are all subjected to a thorough peer-review process, and there was no manuscript that has been accepted for publication without an improvement suggested or requested by our dedicated reviewers. All of these high standard peer-review processes definitely need a vast of unselfish scientists' devotion. Thus, the journal reaching to today's status is fully credited to the unconditional support from world-wide scientific community in the field.

"Yesterday is over" and the sun rises shining a new day. The journal rocked along the wave of standard medicine and escorted translational medicine, providing insightful understanding of cardiovascular side effects for new drug discovery and development. The new era of medicine is in its dawn, starting from precision medicine and ultimately reaching to reality of personalized medicine. *Cardiovascular Toxicology* will meet this new challenge in the evolving world of medicine, and with its expansion of publication, it not only strives for excellence in existing coverages, but also explores the emerging needs, including biotherapy and cell therapy such as stem cell therapy. I can foresee that in the near future, personalized stem cell medicine will become a mainstay in future medicine, *Cardiovascular Toxicology* is ready to play its unique role.

Looking forward to future development, I, as the editor-in-chief, am assuring that the journal will not only continue to escort new drug discovery and development, but also quickly flock to the new parade of next era of medicine. I, therefore, ask for continued support from our scientific community in the field, and working together, we will reach even higher standard of this unique journal *Cardiovascular Toxicology*.

✉ Y. James Kang
ykang7@uthsc.edu

¹ Regenerative Medicine Research Center, Sichuan University West China Hospital, Chengdu, China

² Memphis Institute of Regenerative Medicine, University of Tennessee Health Science Center, Memphis, TN, USA